Morgan Stanley’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.25B | Sell |
23,299,295
-213,439
| -0.9% | -$29.9M | 0.2% | 83 |
|
|
2025
Q4 | $2.89B | Sell |
23,512,734
-222,042
| -0.9% | -$27M | 0.17% | 98 |
|
|
2025
Q3 | $2.63B | Buy |
23,734,776
+899,667
| +4% | +$102M | 0.16% | 113 |
|
|
2025
Q2 | $2.53B | Buy |
22,835,109
+3,034,129
| +15% | +$323M | 0.16% | 109 |
|
|
2025
Q1 | $2.22B | Sell |
19,800,980
-269,483
| -1% | -$27.8M | 0.16% | 113 |
|
|
2024
Q4 | $1.85B | Buy |
20,070,463
+2,821,905
| +16% | +$254M | 0.13% | 135 |
|
|
2024
Q3 | $1.45B | Sell |
17,248,558
-2,088,746
| -11% | -$159M | 0.1% | 176 |
|
|
2024
Q2 | $1.33B | Buy |
19,337,304
+1,323,720
| +7% | +$88.3M | 0.1% | 181 |
|
|
2024
Q1 | $1.32B | Sell |
18,013,584
-17,589,852
| -49% | -$1.35B | 0.11% | 183 |
|
|
2023
Q4 | $2.88B | Buy |
35,603,436
+18,693,817
| +111% | +$1.45B | 0.13% | 147 |
|
|
2023
Q3 | $1.27B | Buy |
16,909,619
+158,794
| +0.9% | +$12.2M | 0.13% | 148 |
|
|
2023
Q2 | $1.29B | Buy |
16,750,825
+643,281
| +4% | +$51.3M | 0.13% | 152 |
|
|
2023
Q1 | $1.34B | Sell |
16,107,544
-1,089,406
| -6% | -$90.2M | 0.14% | 141 |
|
|
2022
Q4 | $1.48B | Buy |
17,196,950
+1,780,489
| +12% | +$141M | 0.17% | 127 |
|
|
2022
Q3 | $951M | Sell |
15,416,461
-2,410,165
| -14% | -$152M | 0.13% | 160 |
|
|
2022
Q2 | $1.1B | Buy |
17,826,626
+4,321,514
| +32% | +$268M | 0.14% | 145 |
|
|
2022
Q1 | $803M | Sell |
13,505,112
-2,124,284
| -14% | -$136M | 0.11% | 192 |
|
|
2021
Q4 | $1.13B | Buy |
15,629,396
+229,768
| +1% | +$15.8M | 0.14% | 157 |
|
|
2021
Q3 | $1.08B | Buy |
15,399,628
+4,409,756
| +40% | +$310M | 0.14% | 159 |
|
|
2021
Q2 | $757M | Buy |
10,989,872
+1,702,366
| +18% | +$114M | 0.1% | 198 |
|
|
2021
Q1 | $600M | Buy |
9,287,506
+2,163,164
| +30% | +$139M | 0.09% | 210 |
|
|
2020
Q4 | $415M | Buy |
7,124,342
+1,106,826
| +18% | +$66.8M | 0.06% | 261 |
|
|
2020
Q3 | $380M | Buy |
6,017,516
+189,169
| +3% | +$13.1M | 0.07% | 239 |
|
|
2020
Q2 | $448M | Sell |
5,828,347
-645,126
| -10% | -$49.4M | 0.1% | 189 |
|
|
2020
Q1 | $484M | Buy |
6,473,473
+917,009
| +17% | +$63.4M | 0.13% | 155 |
|
|
2019
Q4 | $361M | Buy |
5,556,464
+695,452
| +14% | +$45.3M | 0.08% | 223 |
|
|
2019
Q3 | $308M | Sell |
4,861,012
-418,850
| -8% | -$27.4M | 0.08% | 246 |
|
|
2019
Q2 | $357M | Buy |
5,279,862
+511,206
| +11% | +$33.6M | 0.09% | 212 |
|
|
2019
Q1 | $310M | Sell |
4,768,656
-642,654
| -12% | -$42.7M | 0.09% | 243 |
|
|
2018
Q4 | $338M | Sell |
5,411,310
-387,335
| -7% | -$27.1M | 0.1% | 204 |
|
|
2018
Q3 | $448M | Sell |
5,798,645
-151,402
| -3% | -$11.4M | 0.11% | 188 |
|
|
2018
Q2 | $422M | Sell |
5,950,047
-596,611
| -9% | -$42.1M | 0.11% | 183 |
|
|
2018
Q1 | $494M | Sell |
6,546,658
-3,406,283
| -34% | -$271M | 0.14% | 151 |
|
|
2017
Q4 | $713M | Buy |
9,952,941
+983,989
| +11% | +$74.7M | 0.2% | 107 |
|
|
2017
Q3 | $727M | Sell |
8,968,952
-201,350
| -2% | -$15.4M | 0.22% | 100 |
|
|
2017
Q2 | $649M | Buy |
9,170,302
+564,597
| +7% | +$37.6M | 0.2% | 113 |
|
|
2017
Q1 | $584M | Sell |
8,605,705
-897,552
| -9% | -$63.1M | 0.18% | 124 |
|
|
2016
Q4 | $681M | Buy |
9,503,257
+334,454
| +4% | +$24.9M | 0.22% | 91 |
|
|
2016
Q3 | $725M | Sell |
9,168,803
-256,367
| -3% | -$20.8M | 0.25% | 81 |
|
|
2016
Q2 | $786M | Sell |
9,425,170
-248,376
| -3% | -$22M | 0.28% | 66 |
|
|
2016
Q1 | $889M | Sell |
9,673,546
-940,580
| -9% | -$84.8M | 0.34% | 46 |
|
|
2015
Q4 | $1.07B | Buy |
10,614,126
+1,616,773
| +18% | +$168M | 0.39% | 36 |
|
|
2015
Q3 | $883M | Buy |
8,997,353
+1,950,391
| +28% | +$217M | 0.33% | 51 |
|
|
2015
Q2 | $825M | Sell |
7,046,962
-885,322
| -11% | -$96.7M | 0.29% | 65 |
|
|
2015
Q1 | $778M | Sell |
7,932,284
-235,946
| -3% | -$24M | 0.29% | 61 |
|
|
2014
Q4 | $770M | Buy |
8,168,230
+581,813
| +8% | +$60.2M | 0.28% | 65 |
|
|
2014
Q3 | $808M | Buy |
7,586,417
+688,833
| +10% | +$67.4M | 0.31% | 56 |
|
|
2014
Q2 | $572M | Buy |
6,897,584
+909,540
| +15% | +$70.8M | 0.22% | 87 |
|
|
2014
Q1 | $424M | Buy |
5,988,044
+43,784
| +0.7% | +$3.43M | 0.18% | 136 |
|
|
2013
Q4 | $446M | Buy |
5,944,260
+1,145,920
| +24% | +$79.8M | 0.19% | 120 |
|
|
2013
Q3 | $302M | Sell |
4,798,340
-289,834
| -6% | -$17.3M | 0.14% | 170 |
|
|
2013
Q2 | $261M | Buy |
+5,088,174
| New | +$265M | 0.13% | 190 |
|
Other funds holding GILD
VCM
VPM
Morgan Stanley's GILD Position: Q1 2026 in Review
Morgan Stanley reduced its Gilead Sciences (GILD) stake by 0.91% in Q1 2026, selling an estimated $29.9M and leaving 23,299,295 shares worth $3.25B. The position accounts for 0.2% of the portfolio, ranked #83.
Morgan Stanley first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Morgan Stanley held 23,299,295 shares of Gilead Sciences worth $3.25B as of Q1 2026.
- Morgan Stanley sold 213,439 Gilead Sciences shares in Q1 2026, an estimated $29.9M.
- Gilead Sciences made up 0.2% of Morgan Stanley's portfolio in Q1 2026, its #83 holding.
- Morgan Stanley first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.